Search

Displaying results 881 - 890 of 5300 in total
  1. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    Eucalyptus oil can be applied directly to the skin for pain and swelling of respiratory tract mucous membranes, joint pain, genital herpes, and nasal stuffiness.

    Mixtures: HO YAN HOR MEDICATED OIL, Kalaya Pain Relief 6X with Arnica
  2. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus. … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).

  3. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

  4. Drug

    Thallous chloride

    go.drugbank.com/drugs/DB09316
    ApprovedWithdrawn

    Thallous chloride (also known as Thallium(I) chloride) is a colourless solid intermediate in the isolation of thallium from its ores. It is created from the treatment of thallium(I) sulfate with hydrochloric acid. This solid crystallizes...

  5. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.

  6. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involveme...

  7. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inh...

    Products: ETORICOXIB EG, PROKIN-X.
  8. Drug

    Zinc

    go.drugbank.com/drugs/DB01593
    ApprovedInvestigational

    It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. … A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated with traumatic brain injury, stroke, and seizures [A32465].

    Mixtures: Cavan-EC SOD DHA, E & I Formulae
  9. Drug

    Trenonacog alfa

    go.drugbank.com/drugs/DB13201
    Investigational

    Human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.

  10. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug. … [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.